corden pharma peptides APIs, lipid excipients, drug products, injectables, peptides - Corden pharmaexpansion plans a giant investment in its peptide manufacturing business CordenPharma Peptides: Driving Innovation in Pharmaceutical Manufacturing

Corden pharmaexpansion CordenPharma stands at the forefront of the pharmaceutical industry, recognized as one of the leading manufacturers of peptide Active Pharmaceutical Ingredients (APIs).CordenPharma is a leading CDMO for cGMP development & manufacturing ofAPIs, lipid excipients, drug products, injectables, peptides, LNPs, oligos, & osd. With an extensive track record and a commitment to advancing peptide technology, CordenPharma is a pivotal player in the effective production of peptide APIs2025年3月5日—CDMO CordenPharmaplans to spend 500 million eurosto build a new peptide development and manufacturing facility outside of Basel, Switzerland.. The company's dedication to innovation and expansion is evident in its significant investments and strategic developments, solidifying its position as a key partner for peptide development and manufacturingCordenPharma | Full-Service GMP CDMO for a Global Market.

The company's strategic vision includes substantial financial commitments to enhance its capabilities. CordenPharma plans to spend 500 million euros on a new, state-of-the-art peptide manufacturing facility in Switzerland, located at Getec Park in Muttenz. This facility, slated for completion, is part of a broader investment strategy.The Peptides Platform offersmall to large-scale Peptide manufacturingfor GLP-1s, short and long peptides, including oral peptide delivery. In parallel, CordenPharma has announced a major strategic investment exceeding €1 billion to drive its peptide development and manufacturing capabilities forwardTag-Assisted Peptide Synthesis (TAPS). This ambitious plan includes a record investment of approximately €900 million over the next three years to grow its peptide platform. This investment is designed to bolster its GLP-1 peptide manufacturing capacity and expand its capabilities across the United States and Europe. The company aims to reach €1 billion in sales for both its injectable and oral peptides by 2028, underscoring the significant growth anticipated in this sector.

CordenPharma's expertise extends across the entire drug lifecycle, offering bespoke end-to-end CDMO support. For those seeking collaboration, the opportunity to get in touch with our team of experts provides access to unparalleled knowledge in peptide synthesis and manufacturing. The company's comprehensive offerings include APIs, lipid excipients, drug products, injectables, peptides, and more, positioning CordenPharma as a full-service CDMO for a global market. This integrated approach ensures seamless development from early-stage research to commercial production.

Innovation is a cornerstone of CordenPharma's operations2024年7月17日—Will invest approximately 4 million(€900 million) over the next three years in order to enhance its peptide technology platform.. The company is exploring advanced manufacturing techniques, including TAPS (TAG-Assisted Peptide Synthesis), a powerful, cost-effective, and sustainable peptide manufacturing approach. This commitment to novel methodologies ensures efficiency and environmental responsibility in their processes.2025年3月12日—The expansion plans ofCordenPharmaare designed to increase sales in itspeptidebusiness to more than 1 billion euros by 2028. Furthermore, CordenPharma's Peptides Platform offers small to large-scale peptide manufacturing, catering to a diverse range of client needs, including the production of GLP-1s, short and long peptides, and even supporting oral peptide delivery systems.

CordenPharma’s commitment to expanding its manufacturing footprint is also demonstrated by its plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S5 Best Peptide Companies: Trusted Online Vendors in 2025. over the next three years2024年7月17日—The Swiss drug services firm CordenPharmaplans a giant investment in its peptide manufacturing businessover the next 3 years.. This includes commissioning new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs. The company plans a giant investment in its peptide manufacturing business over the next 3 years, aiming to significantly increase its production capacity.2025年3月5日—CordenPharma has finalized plans toestablish a new peptide manufacturing facility in Switzerlandlocated at Getec Park in Muttenz, 8 km outside Basel. This expansion is designed to meet the rising demand for high-quality peptide therapeutics.

The company's strategic collaborations, such as the strong partnership with GENEPEP - PEPTIDE, highlight its dedication to leveraging expertise and advancing peptide drug substance discovery. CordenPharma's investments, totaling approximately $984 million (€900 million) over the next three years, are dedicated to enhancing its peptide technology platform. This proactive approach ensures CordenPharma remains at the cutting edge of pharmaceutical manufacturing, ready to meet the evolving needs of the global healthcare market.CordenPharma Expands Peptide Platform with more than ... The company's consistent focus on growth, innovation, and quality makes CordenPharma a trusted and reliable partner in the complex world of peptide pharmaceutical development and production.